| Symbol | STOK |
|---|---|
| Name | STOKE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 45 WIGGINS AVENUE, BEDFORD, Massachusetts, 01730, United States |
| Telephone | +1 781 430-8200 |
| Fax | — |
| — | |
| Website | https://www.stoketherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001623526 |
| Description | Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Additional info from NASDAQ: |
Ticho Barry 🟡 adjusted position in 4.8K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $32.47 Transaction Date: Aug 14, 2026 | Filing ID: 000019
Read moreKaye Edward M. MD 🟡 adjusted position in 12.6K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $32.47 Transaction Date: Aug 14, 2026 | Filing ID: 000007
Read moreAllan Jonathan 🟡 adjusted position in 2.9K shares (1 derivative) of Stoke Therapeutics, Inc. (STOK) at $32.47 Transaction Date: Aug 14, 2026 | Filing ID: 000012
Read moreStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Read moreNew Form SCHEDULE 13G/A - Stoke Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000902664-26-003525 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Stoke Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000947263-26-000071 <b>Size:</b> 11 KB
Read moreStoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Read more(99% Neutral) STOKE THERAPEUTICS, INC. (STOK) Announces Business Combination
Read more📋 BARUCH TICHO (Officer) plans to sell 21K shares of Stoke Therapeutics, Inc. (at $28.86 each, total $605K) Filed: Aug 03, 2026 | ID: 007565
Read more(10% Negative) STOKE THERAPEUTICS, INC. (STOK) Reports Q3 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorev… | Phase3 | Dravet Syndrome | Recruiting | 2025-06-04 | 2028-10-01 | ClinicalTrials.gov |
| NCT04740476 | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome | Phase2 | Dravet Syndrome | Active_Not_Recruiting | 2021-01-20 | 2029-03-31 | ClinicalTrials.gov |
| NCT04442295 | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending … | Phase1 | Dravet Syndrome | Completed | 2020-06-29 | 2023-11-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| STK-001 - Multiple Ascending Doses | Other | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |
| STK-001 - Single Ascending Doses | Other | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |
| zorevunersen (STK-001) | Other | Phase PHASE2 | Dravet Syndrome | ACTIVE_NOT_RECRUITING | NCT04740476 |
| Sham Comparator | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | Other | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| Sham Comparator | OTHER | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen | DRUG | Phase PHASE3 | Dravet Syndrome | RECRUITING | NCT06872125 |
| zorevunersen (STK-001) | DRUG | Phase PHASE2 | Dravet Syndrome | ACTIVE_NOT_RECRUITING | NCT04740476 |
| STK-001 - Multiple Ascending Doses | DRUG | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |
| STK-001 - Single Ascending Doses | DRUG | Phase PHASE1 | Dravet Syndrome | COMPLETED | NCT04442295 |